Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07536282) titled 'Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection' on April 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Newish Biotech (Wuxi) Co., Ltd.
Condition:
Persistent HPV16 Infection
Intervention:
Biological: NWRD09
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 78
Countries of Recruitment:
United States
To know more, visit ...